Crystal Research Associates, LLC is an independent research firm that provides institutional-quality research on small- and mid-cap companies. The firm is led by veteran Wall Street sell-side analyst Jeffrey Kraws, who is well known by the international financial media for his years of work on Wall Street and for providing consistent award-winning analyses and developing long-term relationships on both the buy-side and sell-side. He has been consistently ranked on Wall Street among the Top Ten Analysts for pharmaceutical stock performance in the world for almost two decades as well as ranked as the Number One Stock Picker in the world for pharmaceuticals by Starmine and for estimates from Zacks. Additionally, Mr. Kraws has been 5-Star Ranked for top biotechnology stock performance by Starmine. Crystal Research Associates' unique and novel product, the Executive Informational Overview® (EIO®), is free of investment ratings, target prices, and forward-looking financial models. The EIO® presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO® details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, West Palm Beach, Montréal, and Toronto.Specialties Healthcare/Pharma/Biotech, Technology, Telecommunications, Resources/Energy, Special Situations

Grannus Securities ("Grannus") is a boutique corporate advisory and funds management practice focused on the innovation and technology markets. Founded in 2005 in Melbourne, Australia, the practice has grown to incorporate projects and investments across the Australia, New Zealand and selected Asian geographies. Grannus is currently sounding the market with a view to launching a venture fund with a minimum US$120 million, known as the Grannus PanAsian Fund. The Fund will be a Guernsey based Limited Partnership, with the Fund Manager, Grannus Venture Partners, being a subsidiary of Grannus Securities. The Fund Manager will have offices in Melbourne and Asia. The Fund will be focused on commercialising technologies emanating primarily from universities and research institutes Australia, Korea, Hong Kong, Malaysia, New Zealand, Singapore and Taiwan. Grannus maintains relationships with the leading universities in the region as a key source of pipeline, and will work with the founders to develop the opportunity and actively manage to exit. Grannus is working with the leading universities, research institutes and companies across the region to identify unique and compelling technologies that will change the way industries, businesses and consumers work and play. By working with, supporting and nurturing early stage companies, either new spin-offs derived from innovative academic research or existing companies, Grannus enables these groundbreaking technologies to be commercialised, products developed and launched whilst maximising the potential return for its investors. The firm's Principals have industry, operational and transaction execution expertise in the healthcare, clean/green technology, applied material sciences, information and communications technology markets working both locally and in the international markets.SpecialtiesHealth Sciences, Clean Technology

Theriva Biologics is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. Synthetic Biologics is developing, or has partnered the development of, product candidates for the treatment of pulmonary arterial hypertension (PAH), relapsing-remitting multiple sclerosis (MS), cognitive dysfunction in MS, fibromyalgia and amyotrophic lateral sclerosis (ALS). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

TopHat Capital provides essential advisory and financial services in the mid-market space: Raising capital, M&A Advisory and financial consulting. The industries we focus on are Real Estate, Bio/Pharma, Financial Services and Distressed. Our unique offering is possible due to 1) our capital relationships that all our partners bring to the firm, 2) our flexibility to structure the deal and 3) swiftness to completion. We do business internationally and with funds both outside and many US funds & family offices. Jeffrey leverages the contacts and relationships he’s made throughout his career, his expertise and experience with both public and private equity, entrepreneurial and Fortune 100 environments to bring financial, operations, relationship building and deal flow expertise to TopHat Capital. He is results-driven with collaborative international approach to achieving business goals. Areas of expertise: Leveraged executive-level relationships & valuable connections to generate significant revenue Successfully worked on and completed raises for hundreds of companies Recognized around the world for expertise in healthcare

Responsible for portfolio advisory and due diligence of new companies under consideration for possible addition to the holdings. Conduct the evaluation of companies as well as helping to solve any of their problems in order to make current companies better positioned and stronger within their sector. Particular strength in providing guidance and solutions to help portfolio companies excel within their specialization with regard to growth and differentiation. Currently working with nine funds with $23.2 billion under management.

Avivagen is a publicly listed biotechnology company trading on the TSX Venture Exchange under the ticker “VIV”. The company has two R&D operations located in the Industrial Partnership Facilities at the National Research Council of Canada (NRC) in Ottawa (Chemistry), and in Charlottetown, Prince Edward Island (Nutriscience). Avivagen is headquartered in Ottawa, Canada and was established August 4th, 2005.

Helping our company to be a major factor in the cardiovascular marketplace. We are now commercial in the United States and in many countries around the world with both our Pharos excimer laser for dermatology as well as our DABRA catheter for faster ablation and higher quality lumen than what is currently available in cardiovascular care. We are using light to saves lives and limbs improving the quality and quantity of health for patients around the world. It is a great feeling to see the positive impact our products have on patients lives.

Piper Sandler (NYSE: PIPR) is a leading investment bank and institutional securities firm.Piper Sandler is a leading middle-market investment bank. Our advisory teams provide unparalleled guidance to clients by combining deep product and sector expertise with ready access to global capital.   Our investment banking group has advised hundreds of clients across our core focus sectors—healthcare, energy, consumer & retail, financial services, agriculture, clean tech & renewables, technology, diversified industrials and business services. With a full suite of products and services, we advise our clients throughout the entire business lifecycle—from private placements and M&A advisory to providing access to the equity and debt capital markets. Commitment to putting our clients’ interest first is the cornerstone of our guiding principles and our success is predicated upon our enduring relationships with our clients and the longevity and continuity of our team of professionals.

Saleen, a company founded by renowned race driver and automotive icon Steve Saleen, is a manufacturer of high-end lifestyle performance vehicles, technical performance parts, lifestyle accessories and apparel. Saleen designs, engineers, tests, certifies, manufactures and assembles all of its own products and vehicles. Current Saleen vehicles are: the 570 and 570X Challenger, the 302 and 302SC Mustang, and the 620 and 620X Camaro.

Purchased half of the firm and significantly positively impacted the business leveraging my contacts and bringing in a large number of new clients as well as adding a new business segment. Worked extensively on business development as well as overall corporate expansion including relocation of existing business.

Ran entire Healthcare team...eventually became Director of Research in addition. Recruited and hired top analysts to join our team spearheading a very successful Healthcare group became a leading group in research. Individuals hired and/or trained by myself even today are major players on both the Buy side and Sell side. Several on the team including myself were able to achieve top recognition for earnings predictability and/or stock performance noted in Wall Street Journal Institutuional Investor, Starmine, Zacks, and other rating services that track and tabulate the performance for investors.

Was responsible for the entire healthcare group

All Operations for the U.S. division of the investment banking and brokerage firm. Was able to successfully grow the business and integrate with all international divisions, interfacing with corporate headquarters management of the overall conglomerate. Built business and obtained all necessary licenses and registrations eventually resulting in successful sale to Unibank giant Danish bank.

I functioned as the Senior Pharmaceutical analyst covering large cap pharma, specialty pharma, drug delivery, generics, and drug distributors. Was able to significantly grow this healthcare area and bring in associates that reported to me, were trained by me and even today are leading analysts in their areas of expertise. Our business sector made significant contributions to the firms overall bottom line.

Responsible for Large Cap pharma, drug delivery , specialty pharmaceuticals and generics. I was the lead analyst on the Burroughs Wellcome Public stock offering which at the time was the largest healthcare IPO in history. The offering was very well placed and successful. Full coverage of both domestic and international companies.

Was responsible for the firms first serious entry into healthcare coverage. I wrote the first report in the United States initiating coverage on Teva Pharmaceuticals with a Strong Buy recommendation. I also initiated and was the first analyst to begin covering the Specialty Pharmaceutical companies including Teva, Roberts Pharmaceuticals, Medeva, Skyepharma, Medicis, and many others. I had early and strong calls on that sector as well as coverage of large capitalization pharmaceutical companies, drug delivery, biotechnology, and drug distributors.

Responsible for competitive analysis and preparation of projects for the senior management and Board of Directors. Worked extensively on mergers and acquisition analysis, budget roll ups, PFIC analysis, 936H, swords tax repatriation, dividend comparisons and policy as well as various other treasury functions.